TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02349906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busilvex
Study: NCT01231737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prulifloxacin
Description: Prulifloxacin 1 tablet/week for 12 weeks.
Study: NCT03739840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.
Study: NCT05285319

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate Only Radiation
Description: Prostate Only Radiation for Intermediate and High Risk Prostate cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate and Pelvic Lymph Node Radiation
Description: Prostate and Pelvic Lymph Node Radiation for Intermediate and High Risk Prostate cancer
Study: NCT04396392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based training
Description: All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based training
Description: All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR-based training
Description: All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to.
Study: NCT00176722

Intervention type: OTHER
Intervention: table tilt
Description: One group randomized to table tilt. One group will be flat.
Study: NCT01796496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative Therapy Techniques
Description: * Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~* Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~* Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction.
Study: NCT03729206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: intravital microscopy
Description: intravital microscopy with sidestream dark-field imaging
Study: NCT01004263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate
Description: Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
Study: NCT03464643

Intervention type: OTHER
Group type: OTHER
Intervention: embryo culture
Description: Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.

Intervention type: OTHER
Group type: OTHER
Intervention: embryo culture
Description: Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
Study: NCT01537354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf®
Description: Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta®
Description: Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
Study: NCT03497182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath sample collection
Description: Subject exhales into breath collection container.
Study: NCT01796496

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Technique
Description: The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
Study: NCT03988816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: 500Mcg Tab, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: once daily
Study: NCT00604929

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate and protein
Description: The intake of carbohydrate and protein during endurance type exercise
Study: NCT01034111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
Study: NCT03640689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovenous ablation + iliac US +/- iliac stenting
Description: Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous ablation of Great Saphenous Vein
Description: Ablation of the Great Saphenous Vein and subsequent Graduated Compression
Study: NCT02909361

Intervention type: DRUG
Intervention: Fulvestrant
Description: 500 mg on days 0, 14, and 28, and every 28 days thereafter
Study: NCT03254069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stainless Steel Crowns
Description: SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
Study: NCT03180411

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
Study: NCT03553940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine
Description: Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent MDCK Inactivated Influenza Vaccine
Description: A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent MDCK Inactivated Influenza Vaccine
Description: A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
Study: NCT02069587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate
Study: NCT04285229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01943084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin Pen®
Description: Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Study: NCT02719730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reimbursement for whole grain purchases
Description: All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
Study: NCT01828515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02628847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00907478

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Description: Romiplostim administered by subcutaneous injection
Study: NCT01945931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Delivery Smartphone Application
Description: The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
Study: NCT02474017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001
Description: Fluticasone Propionate / Salmeterol administered using CRC749 inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRC749 inhaler
Study: NCT03053089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
Study: NCT01748396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Study: NCT03183245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study: NCT01828515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
Study: NCT01704989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLT Laser
Description: At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostagladin
Description: Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
Study: NCT03183245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous fistula (AVF)
Description: Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Procedure that filters a person's blood when their kidneys are no longer functioning properly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Procedure that filters a person's blood when their kidneys are no longer functioning properly
Study: NCT01655069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension
Description: Oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension
Description: Oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension
Description: Oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension
Description: Oral suspension
Study: NCT04491955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: CV301 vaccine consists of MVA-BN-CV301 and FPV-CV301. MVA-BN-CV301 (4 x 10\^8 infectious units/0.5 mL each) will be administered as four subcutaneous injections on D1 and D15. Starting on D29, FPV-CV301 (1 x 10\^9 infectious units/ 0.5mL) will be administered as a single subcutaneous injection every 4 weeks on Arm 1 or every 6 weeks on Arm 2A and 2B for up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
Study: NCT02086799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV thyroxin
Description: Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
Study: NCT04491955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every four weeks on Arm 1. N-803 will be administered at as dose of 10 (Micro)g/kg by SC injection every 4 weeks on Arm 2A and Arm 2B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: NHS-IL12 will be given via subcutaneous injection at a dose of 8 mcg/kg every 4 weeks or 16 mcg/kg for the first 4 injections and 8 mcg/kg thereafter on Arms 2A and 2B.
Study: NCT03646617

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy (HFRT)
Description: The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses. After these 4 doses, the patient and investigator will decide to continue with nivolumab (240 mg) every 2 weeks or Nivolumab (480mg) every 4 weeks as monotherapy for up to one year as an IV infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.